Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008528 · ClinicalTrials.gov registry record · Phase 3
T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs
A Phase 3 study of HIV Infections, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 525
- Enrollment target
- 20
- Study locations
NCT00008528: Completed Phase 3 study of HIV Infections, sponsored by Hoffmann-La Roche.
NCT00008528 is a Phase 3 study of HIV Infections that has completed, run by Hoffmann-La Roche. The registered enrollment target is 525 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00008528, a Phase 3 study of HIV Infections, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 525 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the change in viral load (amount of HIV in the blood) of patients who receive T-20 with selected anti-HIV drugs to that of patients who receive only selected anti-HIV drugs.
Conditions Studied
Interventions
- DRUG Enfuvirtide
Study Locations (20)
California
- Pacific Oaks Med Group - Beverly Hills
- AIDS Healthcare Foundation - Los Angeles
- Univ of California, San Diego - San Diego
- San Francisco Gen Hosp - San Francisco
- San Francisco VA Med Ctr - San Francisco
Massachusetts
- New England Med Ctr - Boston
- Massachusetts Gen Hosp - Boston
- Community Research Initiative of New England - Brookline
Florida
- IDC Research Initiative - Altamonte Springs
- Steinhart Medical Associates - Miami
New York
- Albany Med College - Albany
- Peter Tsang - New York
Alabama
- Univ of Alabama at Birmingham - Birmingham
Arizona
- Phoenix Body Positive - Phoenix
Colorado
- Univ of Colorado Health Sciences Ctr - Denver
District of Columbia
- Whitman Walker Clinic/Elizabeth Taylor Med Ctr - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Phase | Phase 3 |
What the finished NCT00008528 record still lists
NCT00008528 is an interventional study that assigns participants to a tested intervention. The registered 525 participants enrollment target is mid-sized for trials with a published cap, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (18% higher).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Enfuvirtide is the first listed.
NCT00008528 names 20 study sites across 12 states, led by California, Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT00008528 about?
NCT00008528 is a clinical study titled "T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs". The purpose of this study is to compare the change in viral load (amount of HIV in the blood) of patients who receive T-20 with selected anti-HIV drugs to that of patients who receive only selected anti-HIV drugs.
What is the current status of trial NCT00008528?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 525 participants.
What conditions does trial NCT00008528 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00008528?
The interventions under investigation include: Enfuvirtide (DRUG).
Who is sponsoring clinical trial NCT00008528?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00008528 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00008528's enrollment target sits among peer trials
525 59th of 542 higher than 483 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
- NCT06496646 · 525 participants · NA
Antidepressant Adherence for Depressed Adults in Primary Care